Kisspeptin vs PT-141: differences, evidence and safety

Answer first

Kisspeptin, here its short form kisspeptin-10, acts on the kisspeptin receptor in the hypothalamus and briefly raises reproductive hormones. It is approved nowhere. PT-141 (bremelanotide) acts on melanocortin receptors, not on sex hormones, and is approved in the United States for low sexual desire in premenopausal women. No direct comparison could be found.

At a glance

How they work

"Kisspeptin" is the usual search term, but it covers several natural fragments. This page compares the register entry Kisspeptin-10, a chain of ten amino acid building blocks, with PT-141, whose international name is bremelanotide ^[1], ^[2].

Kisspeptin-10

• It acts on nerve cells in the hypothalamus. Binding to the receptor KISS1R makes GnRH neurons release the hormone GnRH. GnRH then tells the pituitary to release luteinising hormone and FSH, which drive the testes or ovaries ^[3], ^[4].
• It does not touch the pituitary directly. It works one step earlier than GnRH, so it fails when the GnRH neurons themselves are damaged ^[5], ^[6].
• It disappears within minutes. The half-life in people is about 3 minutes ^[7].
• The receptor stops responding under a constant signal. Given in pulses, kisspeptin stimulates the hormone axis. Given continuously, it dampens it ^[8], ^[9].

PT-141

• It is a ring of seven building blocks. It was designed as a copy of alpha-melanocyte-stimulating hormone (alpha-MSH), a body signal involved in pigmentation and several brain functions ^[2], ^[10].
• It acts on all five melanocortin receptors. The American label names MC1R and MC4R as the ones that matter. MC4R sits mainly in the brain, MC1R on pigment cells ^[2].
• It is not a sex hormone. It does not act on oestrogen, testosterone or their receptors. The label states that its mechanism in the licensed use is not known ^[2].
• It lasts hours, not minutes. The half-life is about 2.7 hours, and peak levels come after about 1.0 hour ^[2].

The core difference is the route. Kisspeptin works through the hormone chain that ends in the sex glands. PT-141 bypasses that chain and acts on brain receptors of a different family.

What the studies show

No study that compares Kisspeptin-10 and PT-141 directly could be found in the published record reviewed for this page. Neither monograph cites a trial in which both substances appear. The two were studied by different groups, in different people, for different questions.

Kisspeptin-10: hormone levels in healthy men

Physiological study In six healthy men, injections into a vein raised luteinising hormone within 30 minutes, from 4.1 ± 0.4 to 12.4 ± 1.7 IU/L at the middle dose level (p < 0.001). The highest dose level gave a smaller rise than the middle one (p < 0.05) ^[11].

Physiological study Infusions lasting up to 22.5 hours in four men raised luteinising hormone from 5.4 ± 0.7 to 20.8 ± 4.9 IU/L at the higher rate (p < 0.05). Testosterone rose from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/L (p < 0.001) ^[11].

Single-blind, placebo-controlled study One study set kisspeptin-10 against kisspeptin-54 and GnRH in healthy men, five per dose group. At the highest level, the area under the luteinising hormone curve was 10.81 ± 1.73 h·IU/L on kisspeptin-10 and 34.06 ± 5.18 on GnRH. The value for GnRH was higher (p < 0.001). The two kisspeptin fragments did not differ significantly ^[5].

Kisspeptin-10: twelve days, and what continuous dosing did

Randomised, single-blind, placebo-controlled study This study enrolled 15 healthy men across three parts, with 12 controls. Eight-hour infusions under the skin raised luteinising hormone, FSH and testosterone in proportion to the amount given (p < 0.0001) ^[8].

Under five days of continuous infusion, gonadotropin levels matched the dummy arm, so the response was lost. With daily breaks it survived for 12 days. The mean luteinising hormone change was +1.68 ± 0.25 on day 1 and +1.14 ± 0.33 on day 12. On the dummy it was −0.16 ± 0.19 (p = 0.003) ^[8].

Phase 1 studies TAK-448, a longer-acting relative of kisspeptin-10, pushed this further. Under 14 days of continuous infusion, testosterone fell below the starting value within 60 hours and stayed in the castration range from day 8 ^[9].

Terminated Two company phase 2a trials of TAK-448 set out to raise testosterone. Both were stopped, the registry records say, because the main measurement was missed ^[12].

Kisspeptin-10: women respond differently

Physiological study In healthy women in the follicular phase, the first half of the monthly hormone rhythm, gonadotropins did not move. That held for three routes of administration, up to very high amounts. Just before ovulation the same injection into a vein did raise luteinising hormone and FSH ^[13].

Physiological study In 24 women, luteinising hormone rose after the menopause (5.3 ± 0.9 IU/L per hour, p = 0.002). On the combined pill it did not rise significantly (0.9 ± 0.4, p = 0.13) ^[14].

Kisspeptin and sexual desire: a different fragment

Randomised clinical trials, kisspeptin-54 The trials in women and in men with low sexual desire gave kisspeptin-54 into a vein under study conditions. They measured brain activity on scans and scores on psychometric scales, not everyday sexual behaviour ^[15], ^[16].

Kisspeptin-54 lasts about 28 minutes in the body, against about 3 minutes for kisspeptin-10 ^[7]. No study of kisspeptin-10 itself in low sexual desire could be found in the sources reviewed for this page. The kisspeptin-10 studies cited here measured hormone levels, not symptoms or quality of life.

PT-141: sexual desire, the approval endpoint

Phase 3 RCT The two RECONNECT trials randomised 1,267 premenopausal women with acquired, generalised low sexual desire that caused them distress. Both ran 24 weeks against placebo. Desire was scored on a questionnaire domain from 1.2 to 6.0 points ^[2].

Both met their target. The gain over placebo was 0.30 points in study 301 and 0.42 in study 302, both at p < 0.001, and 0.35 combined. Distress, scored from 0 to 4, fell 0.33 points further than on placebo ^[2], ^[17].

PT-141: the outcomes that did not move

Independent re-analysis The number of satisfying sexual events had been the main endpoint of the earlier dose-finding trial. It was replaced for phase 3. A review of the regulator's files found no additional satisfying event, on average ^[18], ^[19].

Phase 2b RCT In that dose-finding trial of 612 women, satisfying events over four weeks rose by 0.2 on placebo and by 0.8 at the highest tested level. The registry gives p < 0.05 for the highest level against placebo ^[19].

Independent re-analysis Dropout because of side effects was far more common than on placebo. The odds ratio was 11.98 (95 per cent confidence interval 3.74 to 38.37). Measured by who finished and chose to continue, the odds favoured placebo at 0.30 (0.24 to 0.38). According to the re-analysis, 72.72 per cent of the endpoints laid down in the trial plans went unreported ^[20].

Phase 1 RCT In an early crossover trial in 18 premenopausal women with arousal difficulty, more women reported moderate or high desire than on placebo (p = 0.0114). Measured vaginal blood flow did not change significantly ^[21].

PT-141: the year-long extension and the male programme

Open-label extension After the core phase, 684 women entered a 52-week extension without a placebo group, and 272 finished it. That attrition limits what the results can carry ^[22].

Phase 1 RCT PT-141 began as a nasal spray for erectile difficulty in men. That programme was abandoned before phase 3 ^[23], ^[24].

Why the figures cannot be set side by side

The kisspeptin-10 figures come from a few healthy volunteers over hours or days, and they measure hormone levels. The PT-141 figures come from premenopausal women with a diagnosis, over 24 weeks, and they measure questionnaire scores. Populations, amounts, endpoints and durations all differ, so none of these numbers can be weighed against the others.

Safety

The safety records differ in kind. PT-141 has a label built on controlled trials in more than a thousand women. Kisspeptin-10 has small, closely watched studies with single-digit to low double-digit numbers of participants.

Kisspeptin-10

• Few adverse events in the studies. The studies reported almost none, but participants were healthy or carefully selected, monitored throughout and given material of known content ^[8], ^[11].
• Continuous dosing turns stimulation into suppression. This is documented in monkeys, in men and with the analogue TAK-448 ^[25], ^[8], ^[9].
• Tissue loss in animals. In adult rats, 13 days of continuous kisspeptin-54 under the skin degenerated the tissue that produces sperm ^[26].
• Analogue side effects. In the TAK-448 programme, 26% of those treated had grade 1 to 2 adverse events ^[9].
• An official risk listing. On 29 September 2023 the FDA placed kisspeptin-10 in category 2 of compounding ingredients that may present significant safety risks. It named immune reactions and peptide-related impurities ^[1].
• Gaps. The longest published human exposure found is 12 days, in seven men. No data on pregnancy, breastfeeding or drug interactions could be found in the sources reviewed ^[8], ^[1].

PT-141

• Nausea in 40.0 per cent against 1.3 per cent on placebo. Giving ondansetron beforehand did not reduce it, according to the label ^[2].
• Other common effects. Flushing affected 20.3 per cent against 0.3 per cent, headache 11.3 against 1.9, and vomiting 4.8 against 0.2 ^[2].
• Blood pressure and pulse. The label gives an average rise of about 6 mmHg systolic and 3 mmHg diastolic. The pulse slows by up to 5 beats per minute. Both usually settle within 12 hours ^[2], ^[27].
• Darker patches of skin. Face, gums and breasts darkened in about 1 per cent under the licensed pattern of use. With daily use in one investigation, the figure was 38 per cent. Not every case faded ^[2].
• Contraindication. The label bars use in uncontrolled high blood pressure or known cardiovascular disease ^[2].
• Serious events. Study 301 recorded 4 of 324 treated women against 1 of 319 on placebo, and no deaths ^[17].
• Gaps. No controlled data beyond 24 weeks and no data on use outside medical care could be found in the sources reviewed ^[22].

Why this page lists no doses. Kisspeptin-10 is an investigational substance approved nowhere. PT-141 is a prescription-only medicine whose label ties its use to a medical check of heart and blood pressure. Amounts for either would read as an instruction rather than a citation, so this page names none ^[1], ^[2].

Legal status

Kisspeptin-10 is approved in none of the seven markets checked, and the FDA lists it as a compounding risk ^[1]. PT-141 was approved in the United States on 21 June 2019 under NDA 210557, prescription-only. Four European register checks found neither an approval nor a withdrawn application ^[28], ^[29]. In sport, kisspeptin is named in class S2.2.1 of the 2026 prohibited list for male athletes ^[30]. PT-141 is not listed, and class S0 does not apply because of the American approval ^[31]. See peptides banned in sport. The monographs reflect the position on 10 and 17 September 2026.

Used together?

The blend directory lists no combination of kisspeptin and PT-141. Its only entry that contains PT-141 pairs it with Melanotan II, a different melanocortin substance approved nowhere.

No study of kisspeptin-10 and PT-141 given together could be found in either monograph. The combinations of PT-141 found in its monograph involve other medicines: sildenafil in men ^[24], and tirzepatide in obesity in a trial that has posted no results ^[32].

The two substances also sit in different legal positions. PT-141 is a licensed medicine in one country, while kisspeptin-10 is approved nowhere and named by the FDA as a compounding risk ^[28], ^[1].

Frequently asked questions

Which is better, Kisspeptin or PT-141?

That cannot be decided from the published record. No study comparing the two could be found in the sources reviewed for this page. In two phase 3 trials in 1,267 premenopausal women, PT-141 raised a desire score by 0.35 points over placebo. The scale runs from 1.2 to 6.0. The published kisspeptin-10 studies measured hormone levels in small groups, not sexual desire.

Is Kisspeptin or PT-141 safer?

No study comparing their safety could be found in the sources reviewed for this page. PT-141 has a label built on large trials, with nausea in 40.0 per cent of treated women and a contraindication for uncontrolled high blood pressure. Kisspeptin-10 has only small, short studies, and the FDA lists it as a compounding ingredient that may present significant safety risks.

What is the difference between Kisspeptin and PT-141?

Kisspeptin acts one step above the hormone GnRH and switches on the chain that ends in luteinising hormone and testosterone. PT-141 acts on melanocortin receptors in the brain and on pigment cells, and does not act on sex hormones. PT-141 is approved in the United States; kisspeptin-10 is approved nowhere.

Can Kisspeptin and PT-141 be taken together?

No study of the two together could be found in the sources reviewed for this page. The blend directory lists no combination of kisspeptin and PT-141. Its only entry with PT-141 pairs it with Melanotan II, a different substance.

What do the studies say about Kisspeptin, PT-141 and sexual desire?

For PT-141, two phase 3 trials measured desire and distress on questionnaires and found small gains over placebo. For kisspeptin, the trials in people with low sexual desire used kisspeptin-54 into a vein and measured brain scans and questionnaires. No study of kisspeptin-10 itself in low sexual desire could be found in the sources reviewed for this page.

Is Kisspeptin-10 the same as the kisspeptin used in the libido studies?

No. Kisspeptin-10 and kisspeptin-54 are two natural pieces of the same gene product. They share the same active tail but last very differently in the body, about 3 minutes against about 28 minutes. The brain imaging and low-desire trials used kisspeptin-54, so their results cannot be read across to kisspeptin-10.

Do Kisspeptin or PT-141 affect testosterone?

Kisspeptin-10 raised testosterone in healthy men during infusions lasting several hours, from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/L. Given continuously, the same class of substance suppressed the hormone axis instead. PT-141 does not act on testosterone, oestrogen or their receptors, according to its American label.

Are Kisspeptin and PT-141 banned in sport?

Kisspeptin is named on the 2026 prohibited list, in class S2.2.1, as a testosterone-stimulating peptide in males, banned at all times. PT-141 is not on the 2026 list. The catch-all class S0 does not reach it either, because an American approval exists.